Overexpression of RAB34 Associates with Tumor Aggressiveness and Immune Infiltration in Glioma

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2022 Oct 12

PMID 36222286

Authors

Peng Hou

Quan Wan

Qing Wang

Xuechao Wu

Xiaojie Lu

Affiliations

Soon will be listed here.

Abstract

RAB34 (RAB34, member RAS oncogene family) is aberrantly expressed in various cancers and exhibits oncogenic properties. However, its function in glioma remains largely unclear. In the present study, we collected 697 RNA-seq data from The Cancer Genome Atlas (TCGA) dataset and 325 RNA-seq data from Chinese Glioma Genome Atlas (CGGA) dataset. Bioinformatics and PCR analysis showed that RAB34 expression was positively related to the glioma tumor grade and predicted poor outcomes for glioma patients. Additionally, RAB34 expression was significantly up-regulated in classical and mesenchymal subtypes, and isolated diastolic hypertension wild-type gliomas. Moreover, RAB34 expression was remarkably correlated with inflammatory activities, immune infiltration, and immune checkpoints in glioma. In vitro experiments demonstrated that inhibition of RAB34 restrained the growth, migration, as well as invasion of glioma cells, and reversed the epithelial-to-mesenchymal transition (EMT) process. Our findings established RAB34 as a novel progression-related biomarker and a possible immunotherapy target for glioma.

Citing Articles

Development and validation of a programmed cell death index to predict the prognosis and drug sensitivity of gastric cancer.

Lin F, Chen X, Liang C, Zhang R, Chen G, Zheng Z Front Pharmacol. 2025; 15:1477363.

PMID: 39744132 PMC: 11688280. DOI: 10.3389/fphar.2024.1477363.

Development of a prognostic model based on lysosome-related genes for ovarian cancer: insights into tumor microenvironment, mutation patterns, and personalized treatment strategies.

Sun R, Li S, Ye W, Lu Y Cancer Cell Int. 2024; 24(1):419.

PMID: 39702158 PMC: 11661007. DOI: 10.1186/s12935-024-03586-w.

Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.

Zhuang Y, Chen J, Mai Z, Huang W, Zhong W J Mol Neurosci. 2024; 74(2):38.

PMID: 38573391 DOI: 10.1007/s12031-024-02216-4.

References

cernochova R, Nekulova M, Holcakova J . [Rab Proteins, Intracellular Transport and Cancer]. Klin Onkol. 2016; 29 Suppl 4(Suppl 4):31-39. View

Xi Y, Shen W, Jin C, Wang L, Yu B . PVT1 Promotes the Proliferation and Migration of Non-Small Cell Lung Cancer via Regulating miR-148/RAB34 Signal Axis. Onco Targets Ther. 2020; 13:1819-1832. PMC: 7054901. DOI: 10.2147/OTT.S222898. View

Ahn B, Pollack I, Okada H . Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel). 2013; 5(4):1379-412. PMC: 3875944. DOI: 10.3390/cancers5041379. View

Wu J, Lu Y, Qin A, Qiao Z, Jiang X . Overexpression of RAB34 correlates with poor prognosis and tumor progression in hepatocellular carcinoma. Oncol Rep. 2017; 38(5):2967-2974. DOI: 10.3892/or.2017.5957. View

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

Dong X, Deng Q, Nie X, Zhang M, Jia W, Chen C . Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma. Exp Mol Pathol. 2015; 98(2):192-9. DOI: 10.1016/j.yexmp.2015.01.013. View

Carril-Ajuria L, Lora D, Carretero-Gonzalez A, Martin-Soberon M, Rioja-Viera P, Castellano D . Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy. Clin Genitourin Cancer. 2020; 19(2):95-102. DOI: 10.1016/j.clgc.2020.10.004. View

Jiang Y, Zhan H . Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. Cancer Lett. 2019; 468:72-81. DOI: 10.1016/j.canlet.2019.10.013. View

Rathi N, McFarland T, Nussenzveig R, Agarwal N, Swami U . Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. Drugs. 2020; 81(2):191-206. PMC: 7932934. DOI: 10.1007/s40265-020-01456-z. View

10.

Chua C, Tang B . Role of Rab GTPases and their interacting proteins in mediating metabolic signalling and regulation. Cell Mol Life Sci. 2015; 72(12):2289-304. PMC: 11113524. DOI: 10.1007/s00018-015-1862-x. View

11.

Becht E, Giraldo N, Lacroix L, Buttard B, Elarouci N, Petitprez F . Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):218. PMC: 5073889. DOI: 10.1186/s13059-016-1070-5. View

12.

Cheng K, Lahad J, Kuo W, Lapuk A, Yamada K, Auersperg N . The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med. 2004; 10(11):1251-6. DOI: 10.1038/nm1125. View

13.

Hass R, von der Ohe J, Ungefroren H . The Intimate Relationship Among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to Be Exploited for Therapeutic Purposes. Cancers (Basel). 2020; 12(12). PMC: 7762343. DOI: 10.3390/cancers12123674. View

14.

Sun L, Xu X, Chen Y, Zhou Y, Tan R, Qiu H . Rab34 regulates adhesion, migration, and invasion of breast cancer cells. Oncogene. 2018; 37(27):3698-3714. DOI: 10.1038/s41388-018-0202-7. View

15.

Bin Z, Dedong H, Xiangjie F, Hongwei X, Qinghui Y . The microRNA-367 inhibits the invasion and metastasis of gastric cancer by directly repressing Rab23. Genet Test Mol Biomarkers. 2014; 19(2):69-74. DOI: 10.1089/gtmb.2014.0210. View

16.

Sun P, Yamamoto H, Suetsugu S, Miki H, Takenawa T, Endo T . Small GTPase Rah/Rab34 is associated with membrane ruffles and macropinosomes and promotes macropinosome formation. J Biol Chem. 2002; 278(6):4063-71. DOI: 10.1074/jbc.M208699200. View

17.

Brandes A, Soesan M, Fiorentino M . Medical treatment of high grade malignant gliomas in adults: an overview. Anticancer Res. 1991; 11(2):719-27. View

18.

Zhang S, Wang Y . [Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2021; 43(1):98-103. DOI: 10.3760/cma.j.cn112152-20191218-00819. View

19.

Ma Q, Long W, Xing C, Chu J, Luo M, Wang H . Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma. Front Immunol. 2019; 9:2924. PMC: 6308128. DOI: 10.3389/fimmu.2018.02924. View

20.

Goldenberg N, Grinstein S, Silverman M . Golgi-bound Rab34 is a novel member of the secretory pathway. Mol Biol Cell. 2007; 18(12):4762-71. PMC: 2096593. DOI: 10.1091/mbc.e06-11-0991. View